Thesis
CTIM-76's 29% ORR in PROC sets up Q3W dosing data as the pivot point for whether this TCE can compete in a crowded late-line ovarian market
CTIM-76 is a T cell engager in Phase 1b targeting platinum-resistant ovarian cancer, a population with high unmet need and no dominant standard of care after multiple lines. The thesis hinges on whether Q3W dosing data confirm durable responses and a manageable CRS profile sufficient to support an accelerated approval pathway. The primary risks are competition from brenetafusp (Immunocore), which is pursuing the same PROC indication with a PRAME-targeting TCR bispecific, and a runway extending only to mid-2027 that may not cover pivotal data generation.
Focus
CTIM-76 Phase 1b Q3W dosing data readout
Q4 2026
Bull
A positive outcome would show maintained or improved ORR (ideally above 35–40%) under Q3W dosing with a favorable CRS profile at or below the 11% Grade 1 rate seen in Phase 1a, alongside evidence of deeper or more durable responses relative to the weekly schedule. This would validate the dosing optimization strategy, support progression into a registrational cohort, and meaningfully de-risk CTIM-76 as a competitive TCE in PROC.
Bear
The most likely failure modes are increased cytokine release syndrome at Q3W dosing intervals due to T cell re-activation dynamics, or loss of response depth if the extended interval allows tumor immune escape between doses. A drop in ORR below the 29% Phase 1a benchmark, or a CRS rate that climbs into Grade 2+ territory at efficacious doses, would signal that the weekly schedule was pharmacologically necessary and that the dosing optimization thesis does not hold.
Unlock the full thesis for CNTX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.